Pancreatic Cancer Research

ResearcherUniversity of California, Los AngelesActive in the last 2 years

Jason M. Link

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6892-0431; OpenAlex author ID A5030632046, A5113261581. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
85
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 5 papers · 2026: 3 papers

Papers 16

  1. Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally advanced pancreatic cancer: a propensity s… Co-author DOI 10.1016/j.gassur.2026.102358↗
  2. Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial. First author DOI 10.1038/s41467-026-68976-2↗
  3. Epigenetic progression of pancreatic cancer to aggressive subtypes involves alternate routes of lineage reprogramming in subtype-intermediate progenitor cells Co-author DOI 10.64898/2026.09.28.754674↗
  4. Protocol to purify and culture human pancreatic cancer cells from patient-derived xenografts. Co-author DOI 10.1016/j.xpro.2025.103672↗
  5. Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer. Co-author DOI 10.1038/s43018-024-00881-3↗
  6. Long Noncoding RNAs Preserve Pancreatic Cancer Identity and Resist Cell Fate Conversion Co-author DOI 10.1101/2025.06.25.661419↗
  7. The Prolyl Isomerase PIN1 Affects Fibroblast Differentiation States and Cross-talk in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-3437↗
  8. A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway Co-author DOI 10.64898/2025.12.12.693851↗
  9. Sendai virus is robust and consistent in delivering genes into human pancreatic cancer cells. Co-author DOI 10.1016/j.heliyon.2024.e27221↗
  10. Clinical and pathological factors associated with survival in patients with pancreatic cancer who receive adjuvant therapy after neoadjuvant therapy: A retrosp… Co-author DOI 10.1016/j.surg.2024.01.008↗
  11. MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell-intrinsic Amplification of Type I IFN Signaling. Co-author DOI 10.1158/1078-0432.ccr-22-3322↗
  12. Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells. Co-author DOI 10.1016/j.celrep.2021.110236↗
  13. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Co-author DOI 10.1158/2159-8290.cd-20-0841↗
  14. Tumor-Infiltrating Leukocyte Phenotypes Distinguish Outcomes in Related Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1200/po.20.00287↗
  15. Acidic fibroblast growth factor underlies microenvironmental regulation of MYC in pancreatic cancer. Co-author DOI 10.1084/jem.20191805↗
  16. MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Co-author DOI 10.1038/s41467-017-01967-6↗

Closest collaborators

The 25 strongest of 85 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rosalie C. Sears · 11 shared papers, 2017–2026 · strength 1.71
  2. Brett C. Sheppard · 8 shared papers, 2017–2026 · strength 1.31
  3. Terry K. Morgan · 5 shared papers, 2021–2025 · strength 0.88
  4. Timothy R. Donahue · 5 shared papers, 2022–2026 · strength 0.86
  5. Motoyuki Tsuda · 4 shared papers, 2025–2026 · strength 0.73
  6. Brittany L. Allen-Petersen · 4 shared papers, 2017–2025 · strength 0.62
  7. Patrick Joseph Worth · 4 shared papers, 2017–2026 · strength 0.61
  8. Dmytro Grygoryev · 3 shared papers, 2024–2025 · strength 0.60
  9. Jungsun Kim · 3 shared papers, 2024–2025 · strength 0.60
  10. Zev A. Wainberg · 3 shared papers, 2024–2026 · strength 0.60
  11. Mark D. Girgis · 3 shared papers, 2024–2026 · strength 0.60
  12. Kevin Hawthorne · 3 shared papers, 2025–2026 · strength 0.57
  13. Ellen M. Langer · 3 shared papers, 2025–2026 · strength 0.57
  14. Lisa M. Coussens · 4 shared papers, 2021–2025 · strength 0.52
  15. Isabel A. English · 3 shared papers, 2025 · strength 0.48
  16. Evan R. Abt · 3 shared papers, 2022–2026 · strength 0.47
  17. Caius Gabriel Radu · 3 shared papers, 2022–2026 · strength 0.47
  18. Jonathan C. King · 2 shared papers, 2026 · strength 0.44
  19. Oscar Joe Hines · 2 shared papers, 2026 · strength 0.44
  20. Charles D. Lopez · 3 shared papers, 2021–2025 · strength 0.43
  21. Julien Tessier · 2 shared papers, 2025 · strength 0.41
  22. Ethan S. Agritelley · 2 shared papers, 2025–2026 · strength 0.40
  23. Shimpei Maeda · 2 shared papers, 2024–2026 · strength 0.39
  24. Takayuki Shimizu · 2 shared papers, 2024–2026 · strength 0.39
  25. Keith D. Lillemoe · 2 shared papers, 2024–2026 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.